Nectin‐2 in ovarian cancer: How is it expressed and what might be its functional role?

Abstract

Nectin‐2 is an adhesion molecule that has been reported to play a role in tumor growth, metastasis and tumor angiogenesis. Herein, we investigated Nectin‐2 in ovarian cancer patients and in cell culture. Tumor as well as peritoneal biopsies of 60 ovarian cancer patients and 22 controls were dual stained for Nectin‐2 and CD 31 using immunohistochemistry. Gene expression of Nectin‐2 was quantified by real‐time PCR and differences analyzed in relation to various tumor characteristics. In the serum of patients, vascular endothelial growth factor ( VEGF ) was quantified by ELISA . Effect of VEGF on Nectin‐2 expression as well as permeability was investigated in HUVEC . In tumor biopsies, Nectin‐2 protein was mainly localized in tumor cells, whereas in peritoneal biopsies, clear colocalization was found in the vasculature. T3 patients had a significantly higher percentage of positive lymph nodes and this correlated with survival. Nectin‐2 was significantly upregulated in tumor biopsies in patients with lymph node metastasis and with residual tumor >1 cm after surgery. Nectin‐2 expression was significantly suppressed in the peritoneal endothelium of patients associated with significantly increased VEGF serum levels. In cell culture, VEGF stimulation led to a significant downregulation of Nectin‐2 which was reversed by VEGF ‐inhibition. In addition, Nectin‐2 knockdown in endothelial cells was associated with significantly increased endothelial permeability. Nectin‐2 expression in ovarian cancer may support tumor cell adhesion, leading to growth and lymph node metastasis. In addition, VEGF ‐induced Nectin‐2 suppression in peritoneal endothelium may support an increase in vascular permeability leading to ascites production.

Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer

“…Next, we performed PVRL2 fluorescent immunohistochemistry on benign/normal ( n = 5) and HGSOC ( n = 15) samples. Mean and maximum intensity was 1.6-fold and 2.4-fold greater, respectively, in HGSOC compared to normal/benign tissue ( p = 0.0021, p = <0.00001) ( Figures 5D–F ), which is in agreement with published studies ( 29 , 30 ).…”

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D

“…DNAM-1 + GM NK-92 cells degranulated against all primary sarcoma explants as well as against the majority of the established cell lines, proving the potential of CD112 and CD155 as tumorspecific markers for targeted immunotherapies (Figures 3, 7). This, along with the absence of the degranulation response of NK cells against healthy donor PBMCs, showed that the use of DNAM-1 + GM NK-92 cells could be restricted/directed only to targets that had elevated CD112 and/or CD155 expression (Figures 2, 7), which is observed in tumors from various origins (65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83), including osteosarcomas (24).…”

The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

“…Lastly, a phase I/II study evaluating poliovirus receptor related immunoglobin domain containing (PVRIG) alone and in combination with nivolumab has been initiated for solid tumors, including ovarian cancer (NCT03667716). Intriguingly, it has been found that PVRIG’s ligand, poliovirus receptor related-2 (PVRL2) is substantially upregulated in EOC [ 108 , 109 ], indicating the potential efficacy of targeting PVRIG along with PD-1.…”